LP6.F LIVZON PHARMAC. GRP H YC1

Healthcare Pharmaceuticals Frankfurt Exchange
8.00 EUR
Close of Nov 12, 2026
1.97 3.14
Market cap
EUR 2.40B
P/E
12.3x
P/B
1.36x
ROE
13.2%
Dividend yield
6.86%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is LP6.F undervalued?

Graham number
Price8.00
Graham value9.28
Discount13.8%

LP6.F trades 13.8% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

LIVZON PHARMAC. GRP H YC1 fundamental analysis

No fundamental analysis for LIVZON PHARMAC. GRP H YC1 yet.

LIVZON PHARMAC. GRP H YC1 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About LIVZON PHARMAC. GRP H YC1

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the ga…

Full company profile